Frequency of transfusion procedures in dialysis patients during the period 2010-2016 at the General Hospital Pula Dialysis Center

Abstract

Cilj istraživanja: Utvrditi učestalost broja transfuzijskih postupaka kod pacijenata na dijalizi u Općoj bočnici Pula u razdoblju od 2010. do 2016. godin, uspoređujući razdoblje korištenja krat-kodjelujućeg preparata eritropoetina, koji se koristio u svim ordiniranim slučajevima do 2013. Godine, te srednje i dugodjelujućeg preparata eritropoetina, koji se koristio od 2013. do 2016. godine. Nacrt studije: Presječno istraživanje. Materijali i metode: Analizirani su dostupni podaci ispitanika koji su liječeni od kronične bubre-žne bolesti u OB Pula na Odjelu za hemodijalizu te su bili podvrgnuti terapiji eritropoetinom iz-među 2010. i 2016. godine. Promatrane nezavisne varijable jesu: spol, dob, stručna sprema i radni status, dok su korištene ove zavisne varijable: broj transfuzijskih postupaka za svaku godinu i terapija eritropoetinom po vrstama. Uzorak od 2010. do 2012. godine koristio se kao relevantan za terapiju kratkodjelujućim eritropoetinom, dok se uzorak od 2015. do 2016. godine koristio kao relevantan za terapiju srednje i dugodjelujućim eritropoetinom. Godine 2013. i 2014. smatraju se prijelaznim godinama jer su pojedini pacijenti tijekom ovoga razdoblja primali kombiniranu terapi-ju. Rezultati: Najviše pacijenata u sedmogodišnjem razdoblju promatranja imalo je između 70 i 80 godina, srednju stručnu spremu i status umirovljenika. U uzorku prevladavaju muškarci s udjelom od 57,8%. U odnosu na 2010. godinu može se primijetiti konstantan trend opadanja broja prim-ljenih transfuzija. Unatoč anomaliji koja je evidentna u 2014. godini, evidentan je trend opadanja u svim godinama promatranog razdoblja. Godine 2015. udio transfuzija po osobi za uzorak u od-nosu na broj transfuzija po osobi za ukupan broj pacijenata iznosio je 11%, dok je 2016. godine isti udio iznosio 5,9%. Zaključak: Terapija srednje i dugodjelujućim pripravkom eritropoetina kvalitetnija je opcija za hemodijalizirane bolesnike s dijagnozom kroničnog bubrežnog oboljenja, s obzirom da primjena novog srednje i dugodjelujućeg pripravka eritropoetina dovodi do smanjenja broja transfuzijskih postupaka nakon dijalize.Objective: To determine the frequency of transfusion procedures in dialysis patients at Pula Ge-neral Hospital from 2010 to 2016, by comparing the period until 2013, during which short-acting erythropoietin was used in all cases of treatment, and the period from 2013 to 2016 when medi-um- and long-acting erythropoietin were used. Study Design: Cross-sectional study. Materials and Methods: The available data on subjects with chronic kidney disease who un-derwent erythropoietin therapy between 2010 and 2016 at the Pula General Hospital Hemodi-alysis Unit were analyzed. The independent variables observed were as follows: gender, age, pro-fessional qualifications and employment status; the dependent variables: number of transfusion procedures for each year and erythropoietin therapy by type. The sample from the period betwe-en 2010 and 2012 was used as relevant for short-acting erythropoietin therapy, while the sample from 2015 to 2016 was used as relevant for medium- and long-acting erythropoietin therapy. 2013 and 2014 are considered transitional years, since during this period some patients received a combined therapy. Results: The highest number of patients in the seven-year observation period were between 70 and 80 years of age, they had secondary education and were retired. The sample is a male-dominated one, with a share of 57.8%. Compared to 2010, a constant decline in the number of transfusions can be observed. Despite the anomaly in 2014, a declining trend can be seen in all the years in the observed period. In 2015, the share of transfusions per patient for the sample compared to the share of transfusions per person for the total number of patients amounted to 11%, while in 2016 the share was 5.9%. Conclusion: The therapy with medium- and long-acting erythropoietin is a better option for he-modialyzed patients with chronic kidney disease, since the use of new medium- and long-acting erythropoietin resulted in a reduced number of transfusion procedures after dialysis